Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study

  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

A clinical trial of an immunotherapy which consisted of intra-tumoural injections of autologous lymphocytes with human lymphoblastoid interferon was evaluated in 31 patients with intracranial glioblastoma. Immunotherapy was performed after stereotactic biopsy or surgical resection. The treatment was tolerated well by all patients. Three patients showed positive response to immunotherapy as documented by transient regression or stabilization of the tumour size on computed tomography. Nevertheless, there is no significant difference in the survival time of the patients treated with immunotherapy and those not treated. We conclude that this immunotherapeutic regimen is not beneficial in patients with glioblastoma when used as single treatment after tumoural biopsy or resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoural LAK-cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175–182

    PubMed  Google Scholar 

  2. Bloom WH, Carstairs KC, Crompton MR, Mc Kissock W (1960) Autologous glioma transplantation. Lancet 2: 77–78

    PubMed  Google Scholar 

  3. Bloom HJG, Peckham MJ, Richardson AE, Alexander PA, Payne PM (1973) Glioblastoma multiforme: A controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 27: 253–267

    PubMed  Google Scholar 

  4. Braun DP, Penn RD, Harris JE (1984) Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies. Neurosurgery 15: 29–33

    PubMed  Google Scholar 

  5. Djeu JY, Heinbaugh JA, Holden HT, Herberman RB (1979) Augmentation of mouse natural killer activity by interferon and interferon inducers. J Immunol 122: 175–181

    PubMed  Google Scholar 

  6. Einhorn S, Blomgren H, Strander H (1978) Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 22: 405–412

    PubMed  Google Scholar 

  7. Gleave JRW (1985) Surgery for primary brain tumours. In: Bleehen NM (ed) Tumours of the brain. Springer, Berlin Heidelberg New York, pp 101–120

    Google Scholar 

  8. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) The lymphokine-activated killer phenomenon: lysis of natural killerresistant fresh solid tumour cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841

    PubMed  Google Scholar 

  9. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157: 884–897

    PubMed  Google Scholar 

  10. Herberman RR, Ortaldo JR, Bonnard GD (1979) Augmentation by interferon of human natural and antibody-dependent cellmediated cytotoxicity. Nature 277: 221–223

    PubMed  Google Scholar 

  11. Merchant RE, Grant AJ, Merchant LH, Young HF (1988) Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine-activated killer cells and recombinant interleukin-2. Cancer 62: 665–671

    PubMed  Google Scholar 

  12. Merchant RE, Merchant LH, Cook SHS, Mc Vicar DW, Young HF (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumour. Neurosurgery 23: 725–732

    PubMed  Google Scholar 

  13. Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H (1988) An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 94: 47–52

    Google Scholar 

  14. Oya S, Vaquero J, Coca S, Salazar FG, Ramiro J, Escalona J (1989) [In vitro cytotoxicity on glioblastoma cells induced by human interferon and by interferon-activated lymphocytes]. Histol Med 5: 115–116 (Spanish)

    Google Scholar 

  15. Oya S, Vaquero J, Ramiro J, Carrera J, Salazar FG (1988) [Ultrastructural modifications in glioblastoma after intratumoural injection of autologous lymphocytes]. Arch Neurobiol 51: 33–34 (Spanish) (Abstract)

    Google Scholar 

  16. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    PubMed  Google Scholar 

  17. Rosenberg SA (1988) Cancer therapy with Interleukin-2: Immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 6: 403–406

    PubMed  Google Scholar 

  18. Salcman M (1985) Supratentorial gliomas: Clinical features and surgical therapy. In: Wilkins RH, Rengachary SS (eds) Neurosurgery. McGraw-Hill Book Co, New York, pp 579–590

    Google Scholar 

  19. Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T, Ikeda H, Mogami H (1987) Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK-cells and recombinant interleukin-2. J Neurosurg 66: 519–521

    PubMed  Google Scholar 

  20. Takakura K, Miki Y, Kubo O, Ogawa N, Matsutani M, Sano K (1972) Adjuvant immunotherapy for malignant brain tumours. Jpn Clin Oncol 12: 109–120

    Google Scholar 

  21. Trinchieri G, Perussia B (1984) Human natural killer cells: Biologic and pathologic aspects. Lab Invest 50: 489–513

    PubMed  Google Scholar 

  22. Trouillas P (1971) [Immunology and Immunotherapy of brain tumours] Doctoral Thesis. Lyon (French)

  23. Vaquero J, Coca S, Oya S, Martinez R, Ramiro J, Salazar FG (1989) Presence and significance of NK-cells in glioblastoma. J Neurosurg 70: 728–731

    PubMed  Google Scholar 

  24. Vaquero J, Coca S, Oya S, Martinez R, Regidor C, Barbolla L, Salazar FG, Ramiro J (1990) Histological changes in glioblastoma after intratumoural injection of autologous lymphocytes and human lymphoblastoid interferon. Neurosurgery 27: 235–239

    PubMed  Google Scholar 

  25. Vaquero J, Martinez R, Barbolla L, De Haro J, De Oya S, Coca S, Ramiro J (1987) Intrathecal injection of autologous leucocytes in glioblastoma: Circulatory dynamics within the subarachnoid space and clinical results. Acta Neurochir (Wien) 89: 37–42

    Google Scholar 

  26. Vaquero J, Martinez R, Oya S, Coca S, Barbolla L, Ramiro J, Salazar FG (1989) Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma. Acta Neurochir (Wien) 98: 35–41

    Google Scholar 

  27. Vaquero J, Martinez R, Ramiro J, Oya S, Coca S (1987) [Adoptive immunotherapy in malignant gliomas: Preliminary evidence of response to intratumoural injection of autologous lymphocytes]. Neurologia (Esp) 2: 20 (Spanish) (Abstract)

    Google Scholar 

  28. Walker MD, Alexander jr E, Hunt HE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehen EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333–343

    PubMed  Google Scholar 

  29. Young HF, Kaplan A, Regelson W (1977) Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma. A preliminary report. Cancer 40: 1037–1044

    PubMed  Google Scholar 

  30. Young HF, Merchant LH, Cook SHS, Merchant RE (1988) Treatment of recurrent glioblastoma with lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Neurosurgery 23: 261 (Abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurosurgery and Haematology, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain

    J. Vaquero, R. Martínez, J. Ramiro, F. G. Salazar, L. Barbolla & C. Regidor

  2. Department of Neurosurgery, Hospital Gregorio Maranón, Madrid, Spain

    J. Vaquero, R. Martínez, J. Ramiro, F. G. Salazar, L. Barbolla & C. Regidor

Authors
  1. J. Vaquero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Ramiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. G. Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Barbolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Regidor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaquero, J., Martínez, R., Ramiro, J. et al. Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study. Acta neurochir 109, 42–45 (1991). https://doi.org/10.1007/BF01405696

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01405696

Keywords

Search

Navigation